Peripheral Artery Disease Market Set for Significant Expansion by 2034, Driven by Rising Prevalence and Innovation in Endovascular Therapies | DelveInsight

Peripheral Artery Disease (PAD), a common circulatory condition caused by narrowed arteries reducing blood flow to the limbs, affects over 200 million people globally and is often underdiagnosed or mismanaged. PAD significantly increases the risk of cardiovascular events and limb amputations, representing a major unmet need in vascular care.

DelveInsight's new report, "Peripheral Artery Disease (PAD) - Market Insight, Epidemiology, and Market Forecast - 2034," delivers an in-depth analysis of the PAD landscape across the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. The report explores epidemiological trends by age, comorbid conditions (e.g., diabetes and smoking), disease stage (claudication to critical limb ischemia), and treatment history.

The PAD market is poised for steady growth, fueled by increased disease awareness, improved screening protocols, and advancements in minimally invasive treatment options such as drug-coated balloons, stents, atherectomy devices, and revascularization procedures. In parallel, novel pharmacological agents targeting inflammation, thrombosis, and endothelial dysfunction are gaining traction in the clinical pipeline.

With rising global incidence, especially among aging populations and diabetic patients, alongside evolving guidelines for earlier detection and aggressive risk factor management, PAD is drawing increased attention from pharmaceutical and medical device companies. Regulatory support and investment in real-world data are further accelerating innovation.

DelveInsight anticipates a dynamic shift in the PAD treatment paradigm by 2034, driven by next-gen endovascular technologies, combination therapies, and digital health tools enabling remote monitoring and patient engagement. The report projects robust market expansion and strategic opportunities in both therapeutic and interventional segments.

Request a sample and uncover the latest breakthroughs shaping the peripheral artery disease market landscape and future outlook @ https://www.delveinsight.com/sample-request/peripheral-artery-disease-pad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Some of the key insights of the Peripheral Artery Disease Market Report:
• The peripheral artery disease market is projected to grow at a steady CAGR throughout the forecast period from 2024 to 2034.
• In the 7MM, there were approximately 17.2 million diagnosed prevalent cases of Peripheral Artery Disease (PAD) in 2022.
• These cases are projected to increase at a significant CAGR by 2034.
• The US had the highest diagnosed prevalence, with around 9.5 million cases in 2022.
• EU4 and the UK collectively accounted for about 5.9 million cases.
• Japan reported approximately 1.8 million diagnosed cases in 2022.
• In March 2025, the FDA approved the first generics of XARELTO (rivaroxaban) 2.5 mg tablets, an anticoagulant to prevent deep vein thrombosis in adults with peripheral artery disease and to reduce the risk of major cardiovascular events in adults with coronary artery disease.
• Emerging therapies for peripheral artery disease include REX-001, ACP-01, Honedra, RJX, Engensis, and others.
• Key companies involved in the treatment of peripheral artery disease include NovoNordisk, Takeda, Mercator MedSystems, Inc., Beijing Northland Biotech. Co., Ltd., Ixaka Ltd, Humacyte, Inc., CardioVascular BioTherapeutics, Proteon Therapeutics, ReNeuron Limited, Alucent Biomedical, Athersys, ARCA biopharma, Ambulero, Venturis Therapeutics, and others.

To know in detail about the peripheral artery disease market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: https://www.delveinsight.com/report-store/peripheral-artery-disease-pad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peripheral Artery Disease Overview
Peripheral Artery Disease (PAD) is a common circulatory condition characterized by the narrowing or blockage of arteries, most often in the legs, due to atherosclerosis. This reduction in blood flow can lead to symptoms such as leg pain during walking (claudication), numbness, weakness, or in severe cases, tissue death and limb amputation. PAD is also a major indicator of systemic atherosclerosis and is associated with a higher risk of heart attack and stroke.

The disease affects millions worldwide, particularly older adults and individuals with risk factors such as smoking, diabetes, hypertension, and high cholesterol. Despite its prevalence, PAD often remains underdiagnosed and undertreated.

Diagnosis typically involves physical examination, ankle-brachial index (ABI), imaging techniques (e.g., ultrasound, MRI, CT angiography), and blood tests. Management includes lifestyle modifications (smoking cessation, diet, exercise), pharmacological interventions (antiplatelets, statins, antihypertensives), and in advanced cases, revascularization procedures like angioplasty or bypass surgery.

Ongoing research aims to improve early detection, optimize treatment strategies, and develop novel therapies, particularly for critical limb ischemia (CLI) and treatment-resistant cases. As awareness and diagnostic capabilities improve, the PAD market is expected to see significant growth in the coming years.

Get a free sample for the peripheral artery disease market forecast, size & share analysis report: https://www.delveinsight.com/sample-request/peripheral-artery-disease-pad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peripheral Artery Disease Epidemiology
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.

Peripheral Artery Disease Epidemiology Segmentation:
The peripheral artery disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
• Total Diagnosed Prevalent Cases of Peripheral Artery Disease
• Gender-specific Diagnosed Prevalent Cases of Peripheral Artery Disease
• Age-Specific Diagnosed Prevalent Cases of Peripheral Artery Disease
• Severity-Specific Diagnosed Prevalent Cases of Peripheral Artery Disease

Peripheral Artery Disease Drugs Uptake and Pipeline Development Activities
The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Peripheral Artery Disease throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments.

The Therapeutics Assessment further highlights the Peripheral Artery Disease drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction.

Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Peripheral Artery Disease, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Peripheral Artery Disease therapeutics.

Explore how emerging peripheral artery disease therapies are aligning with evolving patient populations @ https://www.delveinsight.com/report-store/peripheral-artery-disease-pad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peripheral Artery Disease Market Outlook
The treatment landscape for Peripheral Artery Disease (PAD) is broad and multifaceted, encompassing cholesterol reduction, antiplatelet and anticoagulant therapies, peripheral vasodilators, blood pressure management, exercise programs, and smoking cessation. A variety of medications target claudication symptoms, prevent cardiovascular complications, and support limb salvage. Treatment options range from lifestyle changes and pharmacotherapy to endovascular and surgical interventions.

Effective management of PAD helps reduce risks associated with systemic atherosclerosis, such as stroke, heart attack, and severe limb complications including critical limb ischemia and amputation. Despite its prevalence, PAD remains underdiagnosed and undertreated compared to coronary artery disease.

Current treatment approaches include endovascular and surgical revascularization, with endovascular methods playing a crucial role in limb preservation. Beyond surgery, therapeutic angiogenesis through gene and cell therapies is emerging as a promising avenue. Notably, Collategene (HGF plasmid) is the only gene therapy approved in Japan, while numerous cell-based and regenerative therapies-including angiogenic proteins, gene therapy, and chemokines-are under development, potentially transforming the PAD treatment landscape.

Key industry players like Ixaka Ltd (REX-001), Hemostemix (ACP-01), Lisata Therapeutics (Honedra), and Reven Pharmaceuticals, Inc. (RJX) are actively advancing their candidates through clinical trials, signaling a dynamic pipeline focused on improving PAD treatment outcomes. This robust innovation pipeline is expected to significantly impact the market growth and therapeutic options available through 2032 and beyond.

Peripheral Artery Disease Market Drivers
• The growing prevalence of risk factors such as diabetes, hypertension, and smoking increases the incidence of PAD globally.
• Advancements in endovascular therapies and regenerative medicine, including gene and cell therapies, are expanding effective treatment options.

Peripheral Artery Disease Market Barriers
• Underdiagnosis and lack of awareness about PAD result in delayed treatment and limited patient access to therapies.
• High costs and limited reimbursement for advanced therapies, including novel regenerative treatments, restrict widespread adoption.

Scope of the Peripheral Artery Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key Peripheral Artery Disease Companies: NovoNordisk, Takeda, Mercator MedSystems, Inc., Beijing Northland Biotech. Co., Ltd., Ixaka Ltd, Humacyte, Inc., CardioVascular BioTherapeutics, Proteon Therapeutics, ReNeuron Limited, Alucent Biomedical, Athersys, ARCA biopharma, Ambulero, Venturis Therapeutics, and others.
• Key Peripheral Artery Disease Therapies: REX-001, ACP-01, Honedra, RJX, Engensis, and others.
• Peripheral Artery Disease Therapeutic Assessment: Peripheral Artery Disease currently marketed, and Peripheral Artery Disease emerging therapies.
• Peripheral Artery Disease Market Dynamics: Peripheral Artery Disease market drivers and Peripheral Artery Disease market barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• Peripheral Artery Disease Unmet Needs, KOL's views, Analyst's views, Peripheral Artery Disease Market Access and Reimbursement.

To learn more about peripheral artery disease companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/peripheral-artery-disease-pad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Peripheral Artery Disease Market Report Introduction
2. Executive Summary for Peripheral Artery Disease
3. SWOT analysis of Peripheral Artery Disease
4. Peripheral Artery Disease Patient Share (%) Overview at a Glance
5. Peripheral Artery Disease Market Overview at a Glance
6. Peripheral Artery Disease Disease Background and Overview
7. Peripheral Artery Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Peripheral Artery Disease
9. Peripheral Artery Disease Current Treatment and Medical Practices
10. Peripheral Artery Disease Unmet Needs
11. Peripheral Artery Disease Emerging Therapies
12. Peripheral Artery Disease Market Outlook
13. Country-Wise Peripheral Artery Disease Market Analysis (2020-2034)
14. Peripheral Artery Disease Market Access and Reimbursement of Therapies
15. Peripheral Artery Disease Market Drivers
16. Peripheral Artery Disease Market Barriers
17. Peripheral Artery Disease Appendix
18. Peripheral Artery Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.